Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02056392 · ClinicalTrials.gov registry record · Phase 1
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
A Phase 1 study of Solid Tumours, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT02056392: Completed Phase 1 study of Solid Tumours, sponsored by AstraZeneca.
NCT02056392 is a Phase 1 study of Solid Tumours that has completed, run by AstraZeneca. The registered enrollment target is 54 participants, below the 140-participant average among 9 other Solid Tumours trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02056392, a Phase 1 study of Solid Tumours, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the effect of Selumetinib \[AZD6244; ARRY-142886\] \[Hyd-Sulfate\]), on QTc interval in healthy male volunteers.
Primary Outcome
Change from baseline in QTcF at 30 minutes (msec)
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG Selumetinib
- DRUG selumetinib placebo
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
What the finished NCT02056392 record still lists
NCT02056392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 140-participant average among 9 other Solid Tumours trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT02056392 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02056392 about?
NCT02056392 is a clinical study titled "To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers". Study to assess the effect of Selumetinib \[AZD6244; ARRY-142886\] \[Hyd-Sulfate\]), on QTc interval in healthy male volunteers.
What is the current status of trial NCT02056392?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2014-03. Estimated completion is 2014-08.
What conditions does trial NCT02056392 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT02056392?
The interventions under investigation include: Moxifloxacin (DRUG), Selumetinib (DRUG), selumetinib placebo (DRUG).
Who is sponsoring clinical trial NCT02056392?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02056392 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02056392's enrollment target sits among peer trials
54 8th of 9 higher than 2 of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
-
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
COMPLETED · Phase 1
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia